- Home
- EVAX
EVAX
Evaxion Biotech
as 06-27-2025 12:31pm EST
Evaxion AS is in the field of oncology. It used the AI-Immunology platform.
| Founded: | 2008 | Country: | Denmark |
| Employees: | N/A | City: | N/A |
| Market Cap: | 10.8M | IPO Year: | 2021 |
| Target Price: | $10.00 | AVG Volume (30 days): | 125.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.01 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.20 - $17.75 | Next Earning Date: | 08-13-2025 |
| Revenue: | $3,293,000 | Revenue Growth: | 2555.64% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Evaxion Biotech News
EVAX Breaking Stock News: Dive into EVAX Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus
Zacks Small Cap Research
3 days ago
EVAX AI Technology Produces New Vaccine Candidate
MT Newswires
5 days ago
European Equities Traded in the US as American Depositary Receipts Edge Lower in Monday Trading
MT Newswires
11 days ago
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading
GlobeNewswire
25 days ago
Evaxion receives grant funding to design new polio vaccine
Zacks Small Cap Research
25 days ago
EVAX: Grant Illustrates Belief in Technology
GuruFocus.com
a month ago
Evaxion AS (EVAX) Q1 2025 Earnings Call Highlights: Strong Cash Position and Promising Vaccine ...
GlobeNewswire
a month ago
Evaxion announces business update and first quarter 2025 financial results
Compare EVAX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EVAX Evaxion Biotech - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.